Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
March 1, 2021 | Innovation, Medtech, biotech
Leading biotechnology company NovaBiotics Ltd have secured a major licensing deal for their fungal nail treatment
NovaBiotics Ltd, the clinical-stage anti-infectives biotechnology company, today announced that it has entered into a licensing agreement with an undisclosed partner to commercialise its NP213 peptide in a topical (brush/paint-on) nail fungus treatment.
Under the terms of the agreement, NovaBiotics’ commercial partner has exclusive rights in major territories including Europe and Japan (excluding the United States) to market a new topical treatment for mild to moderate nail fungus (onychomycosis) containing NovaBiotics’ proprietary NP213 peptide. Launch of the product as a medical device by the commercial partner via direct-to-consumer healthcare channels such as retail pharmacies is anticipated in 2022. The terms of the agreement are such that NovaBiotics will receive development milestone payments prior to launch and sales royalties thereafter.
Dr Deborah O’Neil, CEO of NovaBiotics, commented:
“We are delighted to have secured not only the most appropriate commercial partner but also the best route to market for a nail fungus product based on NP213. The licensing deal for NP213 is a key revenue-generating inflexion point for NovaBiotics and we look forward to a very successful long-term commercial collaboration with our new partner.”
“NovaBiotics has reached an incredibly exciting stage in its life cycle, not only with recent advancements in our exciting portfolio of therapies for a range of infectious and respiratory disease, but with the commercial landscape for products in this space is more attractive than ever. This is evidenced by the level of recent engagement and interest in our pipeline from the investment and pharma community.”
NovaBiotics has breadth and depth not only across its unique technology platforms and therapy candidates for a range of infectious and respiratory conditions, but also has significant commercial potential in global markets now bolstered by the revenue stream that will be generated through the NP213 licensing deal.
Other recent progress includes NovaBiotics’ novel antimicrobial-immunomodulator, Nylexa®, which is now set to enter phase 3 clinical trials in the UK for COVID-19 and non-COVID pneumonia (in hospitalised patients in ICU settings with mild and severe disease). NovaBiotics secured £1m of UKRI funding to support the manufacture of the Nylexa clinical trial material in 2020.
Lynovex® for cystic fibrosis (CF) is derived from the same aminothiol platform as Nylexa® and is now registration trial-ready in oral form (for infectious pulmonary exacerbations of CF), and phase 1 ready in inhaled form (for the long-term maintenance of respiratory function in CF patients). The next clinical trials for both of the Lynovex® product candidates could commence as soon as H2 2021. NP339, NovaBiotics’ novel antifungal peptide is anticipated as being phase 1 ready as a candidate for invasive fungal disease by H2 2021 and is now being developed as an inhaled antifungal therapy for the treatment of airway infections associated with CF, ABPA and other acute and chronic fungal diseases of the respiratory tract. NP432, derived from NovaBiotics’ antimicrobial peptide platform, is a potently bactericidal peptide and candidate therapy for multidrug resistant bacterial infections.
This content was provided by Onyx Health
Company Details
Latest Content from Onyx Health
Revolutionising healthcare: The crucial role of diagnostics in transforming the NHS
Amid the formidable challenges faced by the NHS, Onyx Health delve into the pivotal role of diagnostics in healthcare transformation, showcasing how collaboration, innovation, and patient-centric approaches are revolutionising healthcare...
Innovating medical education to deliver 21st century healthcare
Technological advancements are reshaping the healthcare industry. Onyx Health's Medical Education Lead, Sarah Seilly, discusses the innovative techniques at the forefront of enhancing patient care.
Onyx Health Welcomes Sarah Seilly as Head of Medical Education
Leading healthcare marketing communications agency, Onyx Health, has bolstered its team with the appointment of a new Head of Medical Education, Sarah Seilly. This strategic addition to the team reflects...
Onyx Health Expands with Two New Appointments
Newcastle-based creative agency Onyx Health has continued to grow and expand with the dual appointments of Rosie Thompson as Account Manager and Modupe Ayeni as a Medical Writer
Sight-saving MedTech sleep mask could save the NHS multimillions
MedTech company PolyPhotonix has had its innovative diabetes sleep mask adopted in the NHS for the first time
Onyx Health Goes for International Growth with New Managing Director
Onyx Health has announced the appointment of Trevor Pill as their new Managing Director. He will be taking over the day-to-day running of the agency from owner and founder Karen...
Onyx Health Expands with Two New Digital Appointments
Onyx Health has expanded its digital content team with the appointments of Hope Johnston as Digital Content Manager and Jordan Carr as Social Media Executive.
Onyx Health Joins Forces with Rare Disease Specialists Actigen
Onyx Health will be working with Actigen to raise awareness of their innovative clinical trial work in rare diseases and the need to develop new treatment solutions.
Onyx Health Announces a "Double Hatrick" of New Appointments
Onyx Health continues to expand with six new appointments to its creative and communication teams, due to increased growth in its international client portfolio work.
Onyx Health Tackles Type 2 Diabetes with Diabetes Lifestyle Doctors
Onyx Health has teamed up with Diabetes Lifestyle Doctors to tackle the diabetes care gap in the NHS and help patients suffering from type 2 diabetes across the UK. (Pictured...